Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 11 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Olanzapine (LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist.
In vitro
Olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. Olanzapine has a receptor profile that is similar to that of clozapine: it is relatively nonselective at dopamine receptor subtypes and it shows selectivity for mesolimbic and mesocortical over striatal dopamine tracts (electrophysiology; Fos).
In vivo
Olanzapine is a potent antagonist at DA receptors (DOPAC levels; pergolide-stimulated increases in plasma corticosterone) and 5-HT receptors (quipazine-stimulated increases in corticosterone), but is weaker at alpha-adrenergic and muscarinic receptors. Olanzapine combined with fluoxetine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline in rat prefrontal cortex, respectively, which are significantly greater than either drug alone. Olanzapine at 0.5 mg/kg, 3 mg/kg and 10 mg/kg (s.c.) dose-dependently increases the extracellular dopamine (DA) and norepinephrine (NE) levels in rat prefrontal cortex, nucleus accumbens and striatum. Olanzapine also increases extracellular levels of a DA metabolite, DOPAC, and tissue concentrations of a released DA metabolite, 3-methoxytyramine. Olanzapine results in an 8-11% reduction in mean fresh brain weights as well as left cerebrum fresh weights and volumes in macaque monkeys. Olanzapine results in substantial increases in adiposity: increased total body fat reflecting marked increases in subcutaneous and visceral adipose stores. Olanzapine results in marked hepatic insulin resistance.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
| ALogP | 2.9 |
|---|
| Isomeri SMILES | CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C |
|---|---|
| WGK Germania | 3 |
| RTECS | XJ9007750 |
| Numero UN | 2811 |
| Gruppo di imballaggio | III |
| Peso molecolare | 312.43 |
| Beilstein | 7655141 |
| Reaxy-Rn | 7655141 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=7655141&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Solubilità | Solubility (25°C) In vitro Water: 34 mg/mL (195.17 mM); DMSO: Insoluble; |
|---|---|
| Punto di fusione (°C) | 192-196°C |
| 1. Huanhuan Yang, Cong Liu, Chuanhong Zhu, Yan Zheng, Juan Li, Qianyun Zhu, Hao Wang, Xiangming Fang, Quan Liu, Man Liang, Zilong Liu. (2023) Determination of ten antipsychotics in blood, hair and nails: Validation of a LC–MS/MS method and forensic application of keratinized matrix analysis. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, [PMID:37406464] [10.1016/j.jpba.2023.115557] |
| 2. Kaikai Han, Jingjie Cui, Shaowei Chen, Tao Yu. (2023) Effects of olanzapine and lithium carbonate antipsychotic agents on dopamine oxidation. ANALYST, 148 (14): (3330-3340). [PMID:37350329] [10.1039/D3AN00270E] |
| 3. Lingzhi Liang, Xia Ren, Junyi Xu, Yurong Ma, Yunlin Xue, Tao Zhuang, Guisen Zhang. (2022) Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia. MOLECULES, 27 (8): (2550). [PMID:35458749] [10.3390/molecules27082550] |
| 4. Feifei Liang, Xiaofang Tan, Shuaishuai Hao, Wenwen Liu, Chenxin Duan, Guisen Zhang, Tao Zhuang, Yin Chen, Chao Hao. (2022) Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate. JOURNAL OF MOLECULAR STRUCTURE, [PMID:] [10.1016/j.molstruc.2022.132340] |
| 5. Ting Jiang, Yingqiong Zhang, Mengru Bai, Ping Li, Wei Wang, Mingyang Chen, Zhiyuan Ma, Su Zeng, Hui Zhou, Huidi Jiang. (2019) Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis. TOXICOLOGY LETTERS, [PMID:31437515] [10.1016/j.toxlet.2019.08.013] |
| 6. Cuilian Guo, Jinxin Liu, Huqun Li. (2020) Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. BIOMEDICINE & PHARMACOTHERAPY, [PMID:33217690] [10.1016/j.biopha.2020.110912] |
| 7. Lu Yang, Zijin Lin, Ruijing Mu, Wenhan Wu, Hao Zhi, Xiaodong Liu, Hanyu Yang, Li Liu. (2024) Neurons enhance blood–brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion. eLife, [PMID:39475379] [10.7554/eLife.96161] |
| 8. Yuying Chen, Qingwei He, Huangjie Lu, Jie Yang, Jiongming Han, Ying Zhu, Ping Hu. (2024) Visualization and correlation of drug release of risperidone/clozapine microspheres in vitro and in vivo based on FRET mechanism. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:38325621] [10.1016/j.ijpharm.2024.123885] |
| 9. Mukhammet N. Gabdulkhaev, Nailya F. Idiyatullina, Khasan R. Khayarov, Artem O. Surov, Marat A. Ziganshin, Valery V. Gorbatchuk. (2025) Using Solid-State Solvent–Water Competition for Effective Preparation of Phase-Pure Metastable Polymorph of Olanzapine. CRYSTAL GROWTH & DESIGN, [PMID:] [10.1021/acs.cgd.5c01154] |
| 10. Wenjia Yang, Lu Zeng, Xinyu Zhang, Xiangrui Li, Qiujin Zhu. (2026) A time-resolved fluorescent signal tag-mediated immunochromatographic assay for the rapid and sensitive detection of fluoxetine. JOURNAL OF FOOD COMPOSITION AND ANALYSIS, [PMID:] [10.1016/j.jfca.2026.108884] |
| 11. Gao Xiang, Hou Yujiao, Lin Fang, Wen Limei, Guo Yali, Kong Weijun, Hu Junping, Yang Jianhua. (2026) A rime-like Au-Pt nanostructured film and polyaniline-MIP based electrochemical sensor for olanzapine detection. MICROCHIMICA ACTA, 193 (4): (233). [PMID:41811539] [10.1007/s00604-026-07857-3] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →